Dec 11 (Reuters) - Sanofi SA :
* TWO COMBINATION VACCINE CANDIDATES FOR PREVENTION OF INFLUENZA AND COVID-19 GRANTED FAST TRACK DESIGNATION IN THE US
* FDA GRANTS FAST TRACK DESIGNATION TO SANOFI COMBINATION VACCINE CANDIDATES
* SECOND CANDIDATE COMBINES FLUBLOK AND NOVAVAX COVID-19 VACCINE
* INITIATES PHASE 1/2 STUDIES FOR COMBINATION VACCINE CANDIDATES
* FIRST CANDIDATE COMBINES FLUZONE HIGH-DOSE AND NOVAVAX COVID-19 VACCINE
* NOVAVAX COVID-19 VACCINE SHOWS BETTER TOLERABILITY THAN MRNA VACCINES
Source text: Further company coverage:
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。